Stock Price Quote

STERLING BIOTECH LTD.

NSE : STERLINBIOBSE : 512299ISIN CODE : INE324C01038Industry : ChemicalsHouse : Sandesara
BSE0.770 (0 %)
PREV CLOSE ( ) 0.77
OPEN PRICE ( ) 0.80
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.77 (38071)
VOLUME 45051
TODAY'S LOW / HIGH ( )0.77 0.85
52 WK LOW / HIGH ( )0.77 0.85
NSE0.700 (0 %)
PREV CLOSE( ) 0.70
OPEN PRICE ( ) 0.65
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 16887
TODAY'S LOW / HIGH( ) 0.65 0.75
52 WK LOW / HIGH ( )0.65 0.75
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 23-03 1985
Management Info
- Chairman - Managing Director
Registered Office

Address Office No. 601,Windfall Building, Sahar Plaza Complex,Near Hotel Kohinoor, (Andheri East) J.b. Nagar,
Mumbai,
Maharashtra-400059

Phone 02249621752/ 2249621753

Email sterling.biotech@perfectdaybio.com

Website www.sterlingbiotech.in

Registrars Details
MUFG Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE, Luxembourg, Singapore

NEWS

21Apr Sterling Biotech informs about complia
Sterling Biotech has informed that it enclosed the Compliance Certificat..
21Apr Sterling Biotech informs about complia
Sterling Biotech has informed that it enclosed the Certificate from Prac..
05Sep NCLAT sets aside NCLT order to liquida
The National Company Law Appellate Tribunal (NCLAT) has set aside the Na..
06Mar Sterling Biotech informs about committ
Sterling Biotech has informed that 14th meeting of Committee of Creditor..
05Mar Sterling Biotech informs about committ
Sterling Biotech has informed that meeting of the 14th Committee of Cred..

Financials

in Millions
QTR Dec 18 ANNUAL 22
Net Profit369.67-2952.32
Gross Profit 528.77 -2899.21
Operating Profit 120.17-450.22
Net Sales 949.474081.11

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Navin Fluorine Intl (BSE)
peergroup  5947.70 (4.26%)
M.Cap ( in Cr)30475.49
Elantas Beck India (BSE)
peergroup  9381.10 (1.94%)
M.Cap ( in Cr)7437.04
Tanfac Industries (BSE)
peergroup  3992.00 (3.21%)
M.Cap ( in Cr)3982.02
Polychem (BSE)
peergroup  2100.00 (2.33%)
M.Cap ( in Cr)84.85
Titan Bio-Tech (BSE)
peergroup  993.55 (5.00%)
M.Cap ( in Cr)821.04

Shareholding Pattern

NON-INSTITUTION 53.43%
FII 5.12%
PROMOTERS 24.64%
FI/BANKS/INSURANCE 0%
MUTUAL FUNDS/UTI 0%
GOVERNMENT 0%

About Sterling Biotech Ltd.

Sterling Biotech Ltd. was incorporated in the year 1985. Its today's share price is 0.77. Its current market capitalisation stands at Rs 20.96 Cr. In the latest quarter, company has reported Gross Sales of Rs. 4568.5 Cr and Total Income of Rs.4767.06 Cr. The company's management includes Philip Chacko Mundanilkunnathil, Heenaben Devjibhai Pankhania, Aftab Mathur, Keyur Anilkumar Parekh, Vishal Jyotindra Gor, Alok Garg, Monisha Prabhu Macedo.

It is listed on the BSE with a BSE Code of 512299 , NSE with an NSE Symbol of STERLINBIO and ISIN of INE324C01038. It's Registered office is at Office No. 601,Windfall Building, Sahar Plaza Complex,Near Hotel Kohinoor, (Andheri East) J.b. NagarMumbai-400059, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Deloitte Haskins & Sells, HS Hathi & Co, JHS & Associates LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.